Valotx
Helsinki, FI · 1 known investors
ValoTx develops oncolytic virus-based immunotherapies that combine viral vector technology with peptide vaccination to treat cancer. The company leverages a patented platform to rapidly create personalized and disease-specific immunotherapies targeting multiple cancer types.